Around 80–90% of cases of prostate cancers are required to measure androgen at initial diagnosis, and endocrine therapy of prostate cancer is directed toward the reduction of serum androgens and inhibition of AR (Wang et al., 2018; Kokal et al., 2020). The gene discussed is AR; the disease is prostate cancer.